DZ Bank Put 2.374 MDGD 21.06.2024/ DE000DQ1YXT6 /
4/24/2024 1:08:29 PM | Chg.+0.220 | Bid9:55:06 PM | Ask- | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.760EUR | +40.74% | - Bid Size: - |
- Ask Size: - |
MEDIGENE AG NA O.N. | 2.374 - | 6/21/2024 | Put |
GlobeNewswire
5/21
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announ...
GlobeNewswire
5/15
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
GlobeNewswire
5/14
Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise
GlobeNewswire
5/6
The Benchmark Company Announces Upcoming Healthcare House Call VIRTUAL One-on-One Investor Conferenc...
GlobeNewswire
5/2
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell R...
GlobeNewswire
5/2
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein
GlobeNewswire
4/25
Medigene presents streamlined 6-day, high stemness TCR-T therapy production process
GlobeNewswire
4/8
Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR ...
GlobeNewswire
3/28
Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire
3/19
Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
GlobeNewswire
3/6
Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Pr...
GlobeNewswire
3/4
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety...
GlobeNewswire
2/29
Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentia...
GlobeNewswire
2/12
Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR...
GlobeNewswire
11/21/2023
Medigene AG Announces Prioritization of Pipeline and Resource Allocation as well as Extension of Cas...